Related Experiment Video
Updated: Jul 6, 2026
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
New taxanes in development
Cristiano Ferlini1, Daniela Gallo, Giovanni Scambia
1Catholic University of the Sacred Heart, Department of Obstetrics and Gynaecology, Lgo A. Gemelli, 8-00168 Rome, Italy. cferlini@rm.unicatt.it
Background:
Taxanes are presently widely employed for the medical treatment of cancer. However, despite the huge clinical success, these agents exhibit clinical problems related to poor drug solubility, toxicity and, in particular, drug resistance.
Objective:
To identify the critical points related to the process of development of novel taxanes.
Methods:
Publicly available data on the paclitaxel and docetaxel analogues, which have entered a clinical development phase in the last 2 years have been taken into consideration. The development involved novel formulations of paclitaxel and novel chemical entities. For each agent in each category the development phase is analysed and a synthetic comment for each category is included.
Results/Conclusions:
Despite all the efforts, until now clinical success with the new development of taxanes has been limited. Moreover, the expected clinical introduction of epothilones could further restrict the space for development of novel taxanes. Despite these facts, some interesting concepts emerged during the process of development and could lead to successful drugs in the forthcoming years.
Insights
Developing novel taxanes faces challenges like poor solubility and drug resistance, limiting clinical success. Future research may overcome these hurdles, offering new cancer treatment options.
Area of Science:
- Oncology
- Medicinal Chemistry
Background:
- Taxanes are crucial in cancer therapy but suffer from poor solubility, toxicity, and drug resistance.
- Addressing these limitations is key for improving patient outcomes.
Purpose of the Study:
- To pinpoint critical factors in the development of new taxane-based cancer drugs.
- To analyze recent advancements in taxane analogue development.
Main Methods:
- Reviewed publicly available data on paclitaxel and docetaxel analogues in clinical development over the past two years.
- Examined novel formulations and new chemical entities of taxanes.
- Analyzed the development phase and provided commentary for each agent and category.
Main Results:
- Limited clinical success has been achieved with newly developed taxanes to date.
- The emergence of epothilones may further constrain the market for novel taxanes.
Conclusions:
- Despite challenges, innovative concepts in taxane development show promise for future therapeutic applications.
- Continued research is essential to overcome existing limitations and realize the full potential of novel taxanes in cancer treatment.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...